NEW YORK, Jan. 21 - Agencourt Bioscience is set to announce on Tuesday that it will provide genomic services to the Mammalian Gene Collection project of the National Institutes of Health.

Terms of the agreement, funded through a federal contract, call for Agencourt to use its Solid Phase Reversible Immobilization technology to sequence tag mammalian cDNAs and help MGC identify and sequence full-length cDNAs, according to Agencourt.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.